These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 16572897)

  • 1. P53, COX-2, iNOS protein expression changes and their relationship with anti-oxidant enzymes in surgically and multi-modality treated esophageal carcinoma patients.
    Kaur T; Khanduja KL; Kaushik T; Kaushik G; Gupta R; Gupta NM; Vaiphei K
    J Chemother; 2006 Feb; 18(1):74-84. PubMed ID: 16572897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay between oncoproteins and antioxidant enzymes in esophageal carcinoma treated without and with chemoradiotherapy: a prospective study.
    Kaur T; Gupta R; Vaiphei K; Kapoor R; Gupta NM; Khanduja KL
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):563-71. PubMed ID: 18207033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Weiner LM; Colarusso P; Goldberg M; Dresler C; Coia LR
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-93-S19-95. PubMed ID: 9427276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
    Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between inducible nitric oxide synthase expression and p53 status in human esophageal squamous cell carcinoma.
    Matsumoto M; Furihata M; Kurabayashi A; Araki K; Sasaguri S; Ohtsuki Y
    Oncology; 2003; 64(1):90-6. PubMed ID: 12457036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
    Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
    Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Three cases of esophageal carcinoma achieved a pathological complete response after neoadjuvant chemotherapy with cisplatin and 5-fluorouracil].
    Oyanagi H; Ichikawa H; Kosugi S; Banba T; Hanyu T; Hirashima K; Ishikawa T; Kameyama H; Kobayashi T; Minagawa M; Koyama Y; Wakai T
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):497-501. PubMed ID: 25963701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy.
    France M; Drew PA; Dodd T; Watson DI
    Dis Esophagus; 2004; 17(2):136-40. PubMed ID: 15230726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in antioxidant defense status in response to cisplatin and 5-FU in esophageal carcinoma.
    Kaur T; Khanduja KL; Gupta R; Gupta NM; Vaiphei K
    Dis Esophagus; 2008; 21(2):103-7. PubMed ID: 18269643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma.
    Nakashima S; Natsugoe S; Matsumoto M; Kijima F; Takebayashi Y; Okumura H; Shimada M; Nakano S; Kusano C; Baba M; Takao S; Aikou T
    Anticancer Res; 2000; 20(3B):1933-7. PubMed ID: 10928129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer.
    Shimada H; Okazumi S; Takeda A; Nabeya Y; Matsubara H; Funami Y; Hayashi H; Gunji Y; Suzuki T; Ochiai T
    Surg Today; 2001; 31(7):591-6. PubMed ID: 11495153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
    Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
    Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.
    Govindan R; McLeod H; Mantravadi P; Fineberg N; Helft P; Kesler K; Hanna N; Stoner C; Ansari R; Fox E
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):18-21. PubMed ID: 15685829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
    Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.
    Saha AK; Sutton C; Rotimi O; Dexter S; Sue-Ling H; Sarela AI
    Ann Surg Oncol; 2009 May; 16(5):1364-70. PubMed ID: 19252949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodality treatment in the management of esophageal cancer: neoadjuvant chemoradiotherapy followed by transhiatal esophagectomy.
    Irwin JF; Waterfield W; Poussin-Rosillo H; Sardi A
    Md Med J; 1997 Oct; 46(9):471-76. PubMed ID: 9327648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.